Compare Stocks: CLYM, RCUS, VCYT, and DYN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$14.05 -0.1%	$14.29	$1.54 ▼ $18.33	$807.55M	0.09	1.59 million shs	4.05 million shs
DYN Dyne Therapeutics	$17.11 -5.3%	$24.00	$11.92 ▼ $27.31	$3.37B	1.08	2.97 million shs	4.85 million shs
RCUS Arcus Biosciences	$25.30 -1.0%	$28.40	$12.11 ▼ $31.74	$3.25B	0.81	1.43 million shs	2.90 million shs
VCYT Veracyte	$39.79 -1.9%	$47.29	$29.45 ▼ $60.91	$3.26B	1.93	1.20 million shs	2.67 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	-0.07%	-1.40%	-18.97%	+22.71%	+562.74%
DYN Dyne Therapeutics	-5.26%	-6.04%	-36.11%	-13.59%	+30.11%
RCUS Arcus Biosciences	-1.23%	+2.73%	-16.50%	+3.72%	+110.63%
VCYT Veracyte	-1.92%	-2.64%	-5.69%	-25.81%	+25.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$14.05 -0.1%	$14.29	$1.54 ▼ $18.33	$807.55M	0.09	1.59 million shs	4.05 million shs
DYN Dyne Therapeutics	$17.11 -5.3%	$24.00	$11.92 ▼ $27.31	$3.37B	1.08	2.97 million shs	4.85 million shs
RCUS Arcus Biosciences	$25.30 -1.0%	$28.40	$12.11 ▼ $31.74	$3.25B	0.81	1.43 million shs	2.90 million shs
VCYT Veracyte	$39.79 -1.9%	$47.29	$29.45 ▼ $60.91	$3.26B	1.93	1.20 million shs	2.67 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	-0.07%	-1.40%	-18.97%	+22.71%	+562.74%
DYN Dyne Therapeutics	-5.26%	-6.04%	-36.11%	-13.59%	+30.11%
RCUS Arcus Biosciences	-1.23%	+2.73%	-16.50%	+3.72%	+110.63%
VCYT Veracyte	-1.92%	-2.64%	-5.69%	-25.81%	+25.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.00	Buy	$26.92	91.62% Upside
DYN Dyne Therapeutics	2.81	Moderate Buy	$32.17	88.00% Upside
RCUS Arcus Biosciences	2.64	Moderate Buy	$38.30	51.40% Upside
VCYT Veracyte	2.82	Moderate Buy	$55.78	40.18% Upside

Current Analyst Ratings Breakdown

Latest CLYM, RCUS, VCYT, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	RCUS Arcus Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/16/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/15/2026	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	RCUS Arcus Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/9/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/9/2026	DYN Dyne Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$45.00 ➝ $36.00
9/9/2026	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $65.00
9/9/2026	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $26.00
9/9/2026	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$35.00 ➝ $30.00
9/9/2026	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Underweight	$17.00 ➝ $10.00
9/9/2026	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $65.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
RCUS Arcus Biosciences	$247M	13.04	N/A	N/A	$5.84 per share	4.33
VCYT Veracyte	$517.15M	6.19	$1.46 per share	27.24	$16.57 per share	2.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)
VCYT Veracyte	$66.35M	$1.41	28.22	25.84	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest CLYM, RCUS, VCYT, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	31.45	31.45
DYN Dyne Therapeutics	0.28	12.02	12.02
RCUS Arcus Biosciences	0.22	3.82	3.82
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
DYN Dyne Therapeutics	96.68%
RCUS Arcus Biosciences	92.89%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	2.60%
DYN Dyne Therapeutics	9.46%
RCUS Arcus Biosciences	7.60%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	29	57.44 million	55.94 million	N/A
DYN Dyne Therapeutics	258	186.75 million	169.08 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable
VCYT Veracyte	755	80.39 million	79.11 million	Optionable

CLYM, RCUS, VCYT, and DYN Headlines

Recent News About These Companies

Squarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYT

September 19 at 3:43 AM | marketbeat.com

Jens Holstein Sells 5,000 Shares of Veracyte (NASDAQ:VCYT) Stock

September 18 at 5:57 AM | americanbankingnews.com

Corient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYT

September 17 at 3:27 AM | marketbeat.com

Veracyte (NASDAQ:VCYT) Director Jens Holstein Sells 5,000 Shares

September 16 at 5:22 PM | marketbeat.com

Shattuck Labs (NASDAQ:STTK) & Veracyte (NASDAQ:VCYT) Financial Comparison

September 16 at 4:16 AM | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by Analysts

September 16 at 2:15 AM | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 16 at 2:13 AM | marketbeat.com

Veracyte Adds Another Stream to Bladder Franchise, UBS Says

September 15, 2026 | marketscreener.comM

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Veracyte, Inc.: Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

September 15, 2026 | finanznachrichten.de

Veracyte Buys Convergent Genomics

September 14, 2026 | finance.yahoo.com

Veracyte Acquires Convergent Genomics For $150 Mln In Cash

September 14, 2026 | rttnews.com

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

September 14, 2026 | globenewswire.com

Why (VCYT) Price Action Is Critical for Tactical Trading

September 13, 2026 | news.stocktradersdaily.comN

Veracyte (NASDAQ:VCYT) Upgraded at UBS Group

September 12, 2026 | marketbeat.com

Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors

September 9, 2026 | gurufocus.com

3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes

September 9, 2026 | zacks.com

Insider Selling: Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares

September 5, 2026 | insidertrades.com

Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares of Stock

September 4, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) CFO Sells 3,652 Shares

September 4, 2026 | marketbeat.com

Phillip Febbo Sells 13,110 Shares of Veracyte (NASDAQ:VCYT) Stock

September 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CLYM, RCUS, VCYT, and DYN Company Descriptions

Climb Bio NASDAQ:CLYM

$14.05 -0.01 (-0.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.34 +0.29 (+2.04%)

As of 09/18/2026 07:56 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Dyne Therapeutics NASDAQ:DYN

$17.11 -0.95 (-5.26%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$17.11 +0.00 (+0.03%)

As of 09/18/2026 07:30 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Arcus Biosciences NYSE:RCUS

$25.30 -0.24 (-0.95%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$25.25 -0.05 (-0.19%)

As of 09/18/2026 07:30 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Veracyte NASDAQ:VCYT

$39.79 -0.78 (-1.92%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$39.52 -0.27 (-0.67%)

As of 09/18/2026 07:59 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLYM, RCUS, VCYT, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLYM, RCUS, VCYT, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLYM, RCUS, VCYT, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CLYM, RCUS, VCYT, and DYN Company Descriptions

Climb Bio NASDAQ:CLYM

Dyne Therapeutics NASDAQ:DYN

Arcus Biosciences NYSE:RCUS

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLYM, RCUS, VCYT, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLYM, RCUS, VCYT, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLYM, RCUS, VCYT, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CLYM, RCUS, VCYT, and DYN Company Descriptions

Climb Bio NASDAQ:CLYM

Dyne Therapeutics NASDAQ:DYN

Arcus Biosciences NYSE:RCUS

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools